20/20 Biolabs, Inc. — Form 8-K
Filed September 10, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 92/100
What the filing says
20/20 Biolabs (total assets ~$6.1M) filed Form 8-K on September 10, 2026, reporting Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard. The filing does not provide specific dollar amounts, percentages, or detailed circumstances in the extracted text; it appears to be a notice of delisting or listing transfer. No counterparties, share counts, or concrete transaction details are disclosed in the available filing materials.
Why this rating
Delisting is existential threat to micro-cap public company; eliminates market access, shareholder liquidity, raises going-concern risk.
Extracted items
Price action (we called it negative)
before filing · preread $0.54 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.